Vaishali Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

Results View source PDF Explain this filing

VAISHALI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.5%Reaction day

₹9.69

prior close

₹9.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-3.1% vs market

Pharmaceuticals peers, median of 157sector+0.1%-2.6% vs sector

On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.6

10m

+1.6

15m

+1.5

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.5+0.6-3.1+0.1-2.6

Next day

-2.4-0.2-2.2-0.7-1.7

-3.8-0.4-3.4-1.1-2.8

+1.1-0.7+1.8-0.9+2.0

-2.3-2.2-0.1-1.9-0.3

-7.0-2.8-4.2-3.1-3.9

-6.0-1.4-4.6-2.1-3.9

15d

-13.3-7.0-6.3-4.7-8.6

-16.7-6.1-10.6-5.0-11.7

-4.6-9.2+4.6-7.8+3.2

-17.6-6.8-10.8-9.5-8.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vaishali Pharma Limited has submitted its financial results for the quarter and half-year ended September 30, 2025 to the stock exchange. This is a standard regulatory filing under listing obligations, confirming timely submission of Q2 FY26 results. The actual financial figures and detailed performance metrics were not disclosed in this notice and would be available in the accompanying results document. Investors will need to review the detailed results for revenue, profit, and other key indicators.

Likely market impact

This is a routine compliance filing with no direct impact on share price. Investors should look at the actual results document for Vaishali Pharma's Q2 FY26 performance, including revenue growth, margins, and profitability, to assess the stock's outlook.